Abstracts tagged "Scleroderma"

Abstract Number: 1641 • 2019 ACR/ARP Annual Meeting
Change in Calcinosis over 1 Year Using the SCTC Radiologic Scoring System for Calcinosis of the Hands in Patients with Systemic Sclerosis
Antonia Valenzuela¹, Melody Chung ², Tatiana S. Rodríguez-Reyna ³, Susanna Proudman ⁴, Murray Baron ⁵, Flavia Castelino ⁶, Vivien Hsu ⁷, Shufeng Li ⁸, David Fiorentino ⁹, Kathryn Stevens ¹⁰ and Lorinda Chung ², ¹Pontificia Universidad Catolica de Chile, Santiago de Chile, Chile, ²Stanford University, Palo Alto, CA, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Royal Adelaide Hospital North Terrace, Adelaide, Australia, ⁵Jewish General Hospital, McGill University, Montreal, Canada, ⁶Harvard University, Boston, MA, ⁷Rutgers- RWJ Medical School, SOUTH PLAINFIELD, NJ, ⁸Division of Immunology and Rheumatology, Department of Medicine, Stanford, Palo Alto, CA, ⁹Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ¹⁰Stanford University, Stanford
Background/Purpose: Calcinosis cutis is a debilitating complication of systemic sclerosis (SSc) affecting one quarter of patients, most frequently involving the hands. We previously developed and…
Abstract Number: 2610 • 2019 ACR/ARP Annual Meeting
Relationship Between Parenchymal and Vascular Features in Systemic Sclerosis-Interstitial Lung Disease: Results from Quantitative Analysis of Chest Computed Tomography
Cosimo Bruni¹, Mariaelena Occhipinti ², Gianna Camiciottoli ³, Maurizio Bartolucci ⁴, Michael Pienn ⁵, Gemma Lepri ¹, Alessio Fabbrizzi ³, Alessandra Tottoli ¹, Giulia Ciardi ³, Dilia Giuggioli ⁶, Giovanna Cuomo ⁷, Francesco Masini ⁷, Andrea Olschewski ⁵, Federico Lavorini ³, Stefano Colagrande ⁸ and Marco Matucci-Cerinic ⁹, ¹Dept. Experimental and Clinical Medicine, Division of Rheumatology, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ²Dept. Experimental and Clinical Medicine, Div. Pneumology and Div. Radiology II, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ³Dept. Experimental and Clinical Medicine, Div. Pneumology, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ⁴Dept. of Services, Div. Emergency-Urgency Radiology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, ⁵Ludwig Boltzmann Institute for Lung Vascular Research, Institute of Physiology, Medical University of Graz, Graz, Austria, ⁶Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Modena, Italy, ⁷Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Naples, Italy, ⁸Dept. Experimental and Clinical Medicine, Div. Radiology II, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ⁹University of Florence, Department of Medicine, Florence, Italy, Florence, Italy
Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension negatively impact on Systemic sclerosis (SSc) prognosis. Chest computed tomography (CT) is the gold standard in…
Abstract Number: 739 • 2019 ACR/ARP Annual Meeting
Does Digital Thermal Monitoring Correlate to Specific Nailfold Videocapillaroscopy Abnormalities?
Mislav Radic¹, Rebecca Overbury ² and Tracy Frech ³, ¹University Hospital Split, Split, Croatia, ²University of Utah, Departments of Pediatrics and Internal Medicine, Division of Rheumatology, Salt Lake City, UT, ³Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT
Background/Purpose: The fingers have specialized structural and functional features for thermoregulation, and are the most common areas of Raynaud’s phenomenon (RP) in systemic sclerosis (SSc).…
Abstract Number: 1643 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use
Madelon Vonk¹, Oliver Distler ², Daniel Furst ³, Eric Hachulla ⁴, Sindhu Johnson ⁵, Shervin Assassi ⁶, Leslie Meng ⁷, Manuel Quaresma ⁸, Margarida Alves ⁸, Emmanuelle Clerisme-Beaty ⁸ and Wim Wuyts ⁹, ¹Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³University of California, Los Angeles, CA, ⁴Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, ⁵Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada, Toronto, Canada, ⁶Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁹Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC)…
Abstract Number: 2611 • 2019 ACR/ARP Annual Meeting
Mesenchymal Stem Cells in Scleroderma: A Systematic Review
Rossana Mejia-Romero ¹, Natalia Aguilera², Juan Pablo Alzate-Granados ³, C Escobar -Soto ⁴, Claudia Mendoza-Pinto ⁵, Mario García-Carrasco ⁵ and Adriana Rojas-Villarraga ⁶, ¹Center for Arthritis and Rehabilitation (CAYRE IPS) ,University of Barcolena, Bogotá, Distrito Capital de Bogota, Colombia, ²Fundacion Universitaria de Ciencias de La Salud-FUCS, Bogotá, Distrito Capital de Bogota, Colombia, ³Fundacion Universitaria de Ciencias de La Salud-FUCS, Bogota, Distrito Capital de Bogota, Colombia, ⁴TRUSTEM, Bogotá, Distrito Capital de Bogota, Colombia, ⁵Systemic Autoimmune Diseases Research Unit, Hospital de Especialidades, UMAE CMNMAC - CIBIOR, Instituto Mexicano del Seguro Social. Department of Rheumatology and Immunology, Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, Mexico, ⁶Fundacion Universitaria de Ciencias de La Salud-FUCS. Hospital Infantil Universitario San José., Bogotá, Distrito Capital de Bogota, Colombia
Background/Purpose: Scleroderma (systemic scleroderma or systemic sclerosis, SSc), is a highly heterogeneous autoimmune disease of unknown etiology, with a high rate of therapeutic failure and…
Abstract Number: 866 • 2019 ACR/ARP Annual Meeting
Evaluation of the Highly Selective Endothelin a Receptor Antagonist Zibotentan in Systemic Sclerosis Associated Chronic Kidney Disease
Edward Stern ¹, Lauren Host ¹, K. Jane Escott ², Peter Gilmour ², Ivy Wanjiku ³, Rachel Ochiel ³, Aine Burns ¹, Robert Unwin ¹, Voon Ong ⁴ and Christopher Denton⁵, ¹University College London, London, United Kingdom, ²AstraZeneca, London, United Kingdom, ³Royal Free Hospital, London, United Kingdom, ⁴UCL Medical School, Royal Free Campus, London, ⁵University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) causes scleroderma renal crisis (SRC) and chronic kidney disease (CKD). A previous open label trial of bosentan suggested possible benefit for…
Abstract Number: 1644 • 2019 ACR/ARP Annual Meeting
Effects of Nintedanib in Patients with Diffuse and Limited Cutaneous Systemic Sclerosis and Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial
Masataka Kuwana¹, Kristin Highland ², Martina Gahlemann ³, Christopher Denton ⁴, Aryeh Fischer ⁵, Maureen Mayes ⁶, Virginia Steen ⁷, Dinesh Khanna ⁸, Yannick Allanore ⁹, Mannaig Girard ¹⁰, Margarida Alves ¹¹, Susanne Stowasser ¹¹ and Oliver Distler ¹², ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁴University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ⁵University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ⁶Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁷Georgetown University, Washington, D.C., USA, Georgetown, ⁸Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁹Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ¹⁰Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ¹¹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Patients with diffuse cutaneous systemic sclerosis (dcSSc) are at greater risk of developing interstitial lung disease (ILD) than patients with limited cutaneous systemic sclerosis…
Abstract Number: 2615 • 2019 ACR/ARP Annual Meeting
Cumulative Incidence, Survival and Predictors of Pulmonary Arterial Hypertension in Disease Subsets of Systemic Sclerosis: PAH Is Not Increased in Limited vs Diffuse Patients by Adjusted Competing Risk Analysis
Tatiana Nevskaya ¹, Yuxuan Jiang ¹, Mianbo Wang ² and Janet Pope³, ¹University of Western Ontario, London, ON, Canada, ²Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, ³Western University, London, ON, Canada
Background/Purpose: Pulmonary arterial hypertension (PAH) is a life-threatening complication of systemic sclerosis (SSc), thought to be more commonly found among the limited cutaneous (lcSSc) compared…
Abstract Number: 868 • 2019 ACR/ARP Annual Meeting
The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud Phenomenon in Early Diffuse Scleroderma: Results of the “Tamer”‘ Study
Robyn Domsic¹, Maureen Laffoon ¹, Balasubramani Goundappa ², Thomas Medsger ¹, Robert Lafyatis ¹ and Steven Wisniewski ¹, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh Epidemiology Data Center, Pittsburgh, PA
Background/Purpose: Statins have pleiotropic effects felt to influence in their beneficial cardiovascular effects. These include increased nitric oxide production and improved endothelial function, modulation of…
Abstract Number: 1645 • 2019 ACR/ARP Annual Meeting
Comparison of Automated Capture and Analysis System of Sublingual Microvessels and Nailfold Videocapillarscopy for Microvascular Assessment in Systemic Sclerosis
Mislav Radic¹, Julie Thomas ² and Tracy Frech ³, ¹University Hospital Split, Split, Croatia, ²University of Utah, Division of Rheumatology, Salt Lake City, UT, ³Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT
Background/Purpose: Similar to nailfold videocapillaroscopy (NVC), automated capture and analysis of sublingual microvessel segments (intravital microscopy) can define vasculopathy, and distinguish systemic sclerosis (SSc) patients…
Abstract Number: 2616 • 2019 ACR/ARP Annual Meeting
Forced Vital Capacity Trajectories for Systemic Sclerosis-associated Interstitial Lung Disease—Analysis from the University of Michigan Scleroderma Cohort
Mirette Habib¹, Sara Jaafar ¹, Annie Park ¹, Suiyuan Huang ¹, Wen Ye ¹, Vivek Nagaraja ¹, Eric White ¹, Kevin Flaherty ² and Dinesh Khanna ³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ³Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Interstitial Lung Disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc) patients. Forced Vital Capacity (FVC, recorded as %…
Abstract Number: 2711 • 2018 ACR/ARHP Annual Meeting
Comparison of Gastric Antral Vascular Ectasia Associated with Systemic Sclerosis with That Associated with Other Diseases: Are There Differences?
Rabeea Mirza¹, Yuxuan Jin², Donald F. Kirby³ and Soumya Chatterjee^1,4, ¹Rheumatic and Immunologic Disease, Cleveland Clinic, Cleveland, OH, ²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ³Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, ⁴Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH
Background/Purpose: Gastric antral vascular ectasia (GAVE) is a pathologic angioectasia with a characteristic endoscopic appearance. Rugal folds with dilated blood vessels radiate from the antrum…
Abstract Number: 2935 • 2018 ACR/ARHP Annual Meeting
A Practical Classification of Systemic Sclerosis Using Subset and Autoantibodies for the Purpose of Early Risk Stratification
Svetlana I. Nihtyanova¹, Emma C. Derrett-Smith², Carmen Maria Fonseca³, Voon H. Ong² and Christopher P. Denton⁴, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Division of Medicine, University College London, London, United Kingdom, ³Department of Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴University College London, London, United Kingdom
Background/Purpose: The Le Roy et al. classification of SSc into limited and diffuse cutaneous subtype remains the most commonly used. Nevertheless, autoantibodies are much better…
Abstract Number: 2939 • 2018 ACR/ARHP Annual Meeting
Clinical Features Associated with Severe Lower Bowel Involvement in Systemic Sclerosis
Eric Dein¹, Laura K. Hummers², Christopher A. Mecoli^3,4 and Zsuzsanna McMahan⁵, ¹Department of Internal Medicine, Johns Hopkins Bayview, Baltimore, MD, ²Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, ³Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵Department of Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Although up to 90% of scleroderma (SSc) patients are affected by gastrointestinal (GI) dysmotility, clinical features of patients with severe lower gastrointestinal involvement are…
Abstract Number: 124 • 2018 ACR/ARHP Annual Meeting
M10, a Small Fragment of the Hepatocyte Growth Factor Receptor, Attenuates Fibrotic Changes in a Murine Model of Scleroderma Lung Disease and in Human Lung Fibroblasts
Tanjina Akter¹, Ilia Atanelishvili¹, Atsushi Noguchi², Galina S. Bogatkevich¹ and Rick Silver³, ¹Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology, Endocrinology and Nephrology,, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Rheumatology, Medical University of SC, Charleston, SC
Background/Purpose: Interstitial lung disease (ILD) is the major cause of mortality among scleroderma (systemic sclerosis, SSc) patients. Extracellular matrix (ECM) deposition is a hallmark of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].